

HR 9127

Mandating Exclusive Review of Individual Treatments (MERIT) Act

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 4, 2022

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 5, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/9127>

Sponsor

Name: Rep. Buchanan, Vern [R-FL-16]

Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Oct 4, 2022
Rep. Ferguson, A. Drew, IV [R-GA-3]	R · GA		Oct 14, 2022
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Oct 14, 2022
Rep. Dunn, Neal P. [R-FL-2]	R · FL		Oct 18, 2022
Rep. Salazar, Maria Elvira [R-FL-27]	R · FL		Oct 21, 2022
Rep. Miller-Meeks, Mariannette [R-IA-2]	R · IA		Oct 25, 2022
Rep. Smith, Adrian [R-NE-3]	R · NE		Oct 25, 2022
Rep. Rutherford, John H. [R-FL-4]	R · FL		Dec 13, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 5, 2022
Ways and Means Committee	House	Referred To	Oct 4, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Mandating Exclusive Review of Individual Treatments (MERIT) Act

This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.

Actions Timeline

- **Oct 5, 2022:** Referred to the Subcommittee on Health.
- **Oct 4, 2022:** Introduced in House
- **Oct 4, 2022:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.